Blocking a Topoisomerase IIα Nuclear Export Signal Sensitizes Human Multiple Myeloma Cells to Topoisomerase II Inhibitors.
Authors: Turner Joel G. , Rowe Thomas C. , Ostrov David A. , Ciaravino Elizabeth J. , Gump Jana L. , Sullivan Daniel M. 
Published: October 2019

Abstract 2850

Poster Board II-826

Background

We have previously demonstrated that topoisomerase IIa (topo IIa) is exported from the nucleus of high density human multiple myeloma (MM) cells by a CRM1-dependent mechanism (Engel et al, Exp. Cell Res. 295(2):421-31, 2004). We have also identified the nuclear export signals (NES) for topo IIa at amino acids 1017-28 (site 1) and 1054-66 (site 2) using mutated full-length FLAG-tagged topo IIa protein and immunofluorescence microscopy (Turner et al, J. Cell Sci. 117:3061-71, 2004). Drug resistance to topo II poisons occurs when topo II is trafficked to the cytoplasm where it is not in contact with the DNA and thus unable to induce cell death in response to topo II inhibitors. In addition, we have recently shown that blocking nuclear export of topo IIα with a CRM1 inhibitor or by siRNA sensitizes MM cells to topo II poisons (Turner et al, Cancer Res. In press).

Materials and Methods

The structure of S. cerevisiae topo II was used to create a model of human topo IIα using the program Protein Homology/analogy Recognition Engine (Phyre), available on the Web (http://www.imperial.ac.uk/phyre). The procedure for molecular docking involved selection of structural pockets of the NES in topo IIa that were suitable for interactions with drug-like small molecule inhibitors (SMI). Molecular docking simulations screened 140,000 small molecules (mw < 500) from the NCI database. The top scoring SMI for each of the two NES (20 total) were obtained from NCI and tested for induction of apoptosis (caspase 3) and anti-proliferative activity using CellTiter-Blue (Promega). Cell types used included human MM RPMI 8226 and NCI-H929 cells. SMI were tested both as single agents and in combination experiments with the topo II inhibitor doxorubicin. In addition, immunofluorescence microscopy for the intracellular location of topo IIα in SMI-treated MM cells was also performed.

Results

Low density myeloma cells:

Robotic cell viability assays determined that several of the SMI had anti-proliferative activity. However, only SMI that docked to NES site 1 showed any inhibition of viability. The IC50 values obtained from single-drug cell viability assays in low density cells revealed two SMI compounds with IC50 values of 4.7 and 11.1 μM. None of the SMI affected the viability of high density cells (IC50 >100 μM).

High density drug-resistant myeloma cells:

Data from apoptosis assays indicated that four of the SMI that docked to NES site 1 significantly (p<0.05) sensitized high density MM cells to doxorubicin. Immunofluorescence microscopy revealed an increase in topo IIα in the cell nucleus of cells treated for 20 hours with the four lead SMI.

Conclusions

Using computer-generated molecular modeling, we have identified four lead compounds from the NCI database that bind to the site 1 NES of topo IIα. These lead compounds are SMI that synergize with the topo II inhibitor doxorubicin. In vitro apoptosis assays indicate that these drugs may be effective as single agents or in combination with currently used cancer drugs that target topo II. These data may have potential clinical implications in the treatment of multiple myeloma.

Disclosures:

Sullivan: Merck: Research Funding; Amgen: Membership on an entity's Board of Directors or advisory committees; Merrion: Membership on an entity's Board of Directors or advisory committees.